. Accuray (Sunnyvale, California), manufacturer of the first radiosurgery system that uses intelligent robotics to treat tumors anywhere in the body, reported that clinicians worldwide are using the CyberKnife Robotic Radiosurgery System to treat tumors outside the head at a rapidly increasing rate. Extracranial tumor treatment now represents more than 50% of all procedures performed with the CyberKnife System in the U.S., with the treatment of lung tumors outpacing all other tumor treatments in the body. Since the July 2004 introduction of the Synchrony Respiratory Tracking System, lung tumor treatments have increased threefold annually. Synchrony allows patients to breathe normally throughout their treatment without uncomfortable breath-holding or radiation beam gating techniques so clinicians can track, detect and correct for tumor and patient movement throughout the treatment minimizing damage to healthy tissue or critical structures.

. ev3 (Plymouth, Minnesota) reported FDA 510(k) clearance to market the Prot g EverFlex Self-Expanding Stent System for the palliative treatment of malignant neoplasms in the biliary tree. Additionally, ev3 obtained the CE mark for the Prot g EverFlex for general use in the peripheral vasculature, including common and external iliac, subclavian and the superficial femoral artery. The company has already begun commercial release throughout Europe. In addition to providing strength and flexibility, the Prot g EverFlex provides similar delivery and deployment to the current Prot g stent family. Available on a 0.035“ compatible delivery platform, the EverFlex is the longest self-expanding nitinol stent available, supplied in lengths up to 150mm. All sizes of the stent will be compatible with a 6 Fr guiding catheter.